Coherus Biosciences Stock Forecast, Price & News

Coherus Biosciences' stock was trading at $15.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CHRS shares have increased by 5.0% and is now trading at $16.67.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Coherus Biosciences.

Coherus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Coherus Biosciences.

Coherus Biosciences will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Coherus Biosciences Inc (NASDAQ:CHRS) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported $0.70 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.44. The biotechnology company earned $135.67 million during the quarter, compared to analyst estimates of $100.33 million. Coherus Biosciences had a net margin of 37.11% and a return on equity of 139.51%.
View Coherus Biosciences' earnings history.

7 equities research analysts have issued twelve-month price objectives for Coherus Biosciences' shares. Their forecasts range from $20.00 to $43.00. On average, they expect Coherus Biosciences' share price to reach $31.43 in the next twelve months. This suggests a possible upside of 88.5% from the stock's current price.
View analysts' price targets for Coherus Biosciences.

Some companies that are related to Coherus Biosciences include Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Vir Biotechnology (VIR), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO), Immunovant (IMVT), Ablynx (ABLYF), bluebird bio (BLUE), Twist Bioscience (TWST), Relay Therapeutics (RLAY), SpringWorks Therapeutics (SWTX), Revolution Medicines (RVMD) and Editas Medicine (EDIT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.99%), Peregrine Capital Management LLC (0.73%), WINTON GROUP Ltd (0.16%), Comerica Bank (0.09%), Foundry Partners LLC (0.08%) and State of Alaska Department of Revenue (0.08%). Company insiders that own Coherus Biosciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom and Vincent R Anicetti.
View institutional ownership trends for Coherus Biosciences.

CHRS stock was sold by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Ziegler Capital Management LLC, Assenagon Asset Management S.A., and Foundry Partners LLC. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, and Vincent R Anicetti.
View insider buying and selling activity for Coherus Biosciences.

CHRS stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, WINTON GROUP Ltd, Candriam Luxembourg S.C.A., DekaBank Deutsche Girozentrale, Louisiana State Employees Retirement System, Pacer Advisors Inc., Standard Life Aberdeen plc, and XTX Markets LLC.
View insider buying and selling activity for Coherus Biosciences.

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CHRS stock can currently be purchased for approximately $16.67.

Coherus Biosciences has a market capitalization of $1.19 billion and generates $356.07 million in revenue each year. The biotechnology company earns $89.83 million in net income (profit) each year or $1.23 on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.

The official website for Coherus Biosciences is www.coherus.com.

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]